In summary, we demonstrate a salutary effect of CXCL10 genetic deletion in a preclinical model of NASH pathogenesis independent of body weight and the metabolic syndrome. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatohepatitis.